Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.35 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18737149 | 0.91 | PLA2G1B (0.39) | SIGMAR1CACNA2D1PLA2G1BPLA2G2AKCNH2 | |
| SCHEMBL21016188 | 0.84 | SIGMAR1 (0.42) | SIGMAR1CACNA2D1KCNH2 | |
| SCHEMBL12394761 | 0.83 | SIGMAR1 (0.36) | SIGMAR1CACNA2D1KCNH2SLC2A1 | |
| SCHEMBL24811724 | 0.82 | KCNH2 (0.33) | SIGMAR1PLA2G1BPLA2G2AKCNH2CA12 | |
| SCHEMBL10284380 | 0.82 | SIGMAR1 (0.41) | SIGMAR1PLA2G1BPLA2G2AKCNH2 | |
| SCHEMBL19478585 | 0.80 | CACNA2D1 (0.33) | SIGMAR1CACNA2D1 | |
| SCHEMBL8897968 | 0.79 | TSHR (0.43) | — | |
| SCHEMBL678643 | 0.77 | SIGMAR1 (0.38) | SIGMAR1CACNA2D1KCNH2SLC2A1 | |
| SCHEMBL27781294 | 0.76 | TSHR (0.40) | — | |
| SCHEMBL22725 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, HLA-DRB1 | SIGMAR1 2497/4885CACNA2D1 2009/4885PLA2G1B 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.